ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

WuXi suggests that investors cool it

by Rick Mullin
June 3, 2018 | APPEARED IN VOLUME 96, ISSUE 23

 

Three weeks after raising $354 million in an initial public offering on the Shanghai Stock Exchange, WuXi AppTec has issued a statement suggesting that investors take a pause. By last week, the Chinese pharmaceutical services firm had seen its stock price rise by the exchange’s 10% daily maximum for 15 days in a row, resulting in a sixfold increase. The company claims its business activities are “normal” but warns investors to be aware of the risks associated with the drug services sector. “The price-earnings ratio of the company is higher than that of comparable listed companies,” WuXi notes.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment